GlassScriptPhysician profile
Maury B Berger
NPI 1457310054
$8,656.79
in general payments reported to CMS, 2019-2025
65 companies · $1,064 in 2025
The $1,064 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $2,103 · 2021: $538 · 2022: $1,190 · 2023: $1,157 · 2024: $975 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Education: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.30 |
| Education | $506.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,343.31 | 2020-2023 | Yescarta |
| Novartis Pharmaceuticals Corporation | $682.09 | 2019-2025 | |
| Pfizer INC. | $600.40 | 2019-2025 | |
| Janssen Biotech, INC. | $593.75 | 2019-2024 | Rybrevant |
| Seagen INC. | $524.47 | 2019-2025 | Tivdak, Adcetris, Tukysa |
| Astellas Pharma US INC | $436.96 | 2019-2025 | Vyloy, Padcev, Xospata |
| Lilly USA, LLC | $292.10 | 2019-2024 | Verzenio |
| Emd Serono, INC. | $246.70 | 2019-2025 | Bavencio |
| Amgen INC. | $246.53 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Astrazeneca Pharmaceuticals LP | $246.08 | 2019-2025 | Calquence |
| Celgene Corporation | $242.30 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Puma Biotechnology, INC. | $209.98 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $200.54 | 2020-2023 | Imbruvica |
| Incyte Corporation | $178.02 | 2022-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $163.76 | 2019-2025 | Opdivo |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maury Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.